<DOC>
	<DOC>NCT00326144</DOC>
	<brief_summary>The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patient is able to provide written informed consent before beginning any study related procedures Patient has a documented clinical diagnosis of major depressive disorder Patient is able to understand and comply with the requirements of the study, as judged by a study investigator Patients with a history of noncompliance as judged by the study investigator Patients with a known lack of response to previous treatment with quetiapine Patients who have participated in a clinical trial within 4 weeks of randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>